Reading that is better than nothing. Let's hope it is objective enough to result as mentionned:
Profits in the $57 Billion Medical Cannabis Boom
A disruptive under-the-radar company has taken the lead in low-priced medical cannabis production that could put it on the road to massive profits. The company has a number of extraordinary competitive advantages that convinced me to take a closer look at what it has to offer investors. And now that I’ve done my due diligence, analyzed the company, spoken with management and even visited medical cannabis farms, I’ve concluded that early investors in Isracann Biosciences Inc. (ISCNF) could profit handsomely. In fact, I believe Isracann Biosciences Inc. could produce potential growth of 740% or more, just like its South American counterpart PharmaCielo.